Niva Bupa IPO Subscription Status
The Niva Bupa IPO has received a positive response from investors. Here are the key subscription figures as of Day 2:
- Overall Subscription: 65%
- Qualified Institutional Buyers (QIBs): Subscribed at 79%
- Retail Individual Investors (RIIs): Subscribed at 70%
- Non-Institutional Investors (NIIs): Subscribed at 33%
On its first day of bidding, the IPO received bids for 11,18,61,400 shares against 17,28,57,143 shares on offer.
Niva Bupa IPO Pricing and Lot Size
- Price Band: The price band for the Niva Bupa IPO is set between ₹70 and ₹74 per share.
- Lot Size: The minimum order quantity is 200 shares, which translates to a total investment of ₹14,000 to ₹14,800 based on the price band.
Grey Market Premium (GMP)
As of today, the grey market premium for Niva Bupa shares is reported to be ₹0, indicating that there is currently no additional investor willingness to pay above the issue price. This could reflect cautious sentiment among potential investors regarding the stock’s performance post-listing.
Important Dates
Here are key dates related to the Niva Bupa IPO that investors should keep in mind:
| Event | Date |
|---|---|
| IPO Subscription Period | November 7 – 11, 2024 |
| Basis of Allotment | November 12, 2024 |
| Refunds Initiated | November 13, 2024 |
| Shares Credited to Demat Accounts | November 14, 2024 |
| Listing Date | November 14, 2024 |
Company Overview
Niva Bupa Health Insurance Company is a prominent player in the Indian health insurance sector. The company aims to provide comprehensive health insurance solutions and has garnered significant interest from institutional and retail investors alike.
Should You Apply for Niva Bupa’s IPO?
Investors considering whether to apply for the Niva Bupa IPO should take into account several factors:
- Strong Institutional Interest: The QIB segment has shown robust demand with a subscription rate of 79%, indicating confidence from institutional investors.
- Retail Demand: The retail segment is also performing well with a subscription rate of 70%, suggesting positive sentiment among individual investors.
- GMP Insights: The current nil GMP may raise concerns about potential listing performance. Investors should consider this factor carefully before making a decision.
- Long-Term Growth Potential: Given the increasing focus on health insurance in India and Niva Bupa’s established presence in this market, some analysts recommend a long-term investment perspective.
- Market Conditions: Investors should also be aware of broader market conditions that could impact stock performance post-listing.
Expert Opinion
Financial experts have mixed views on whether to subscribe to Niva Bupa’s IPO:
- Some analysts emphasize strong fundamentals and growth potential in the health insurance space as compelling reasons to invest.
- Others caution that market conditions can be unpredictable and advise potential investors to conduct thorough research before making investment decisions.
Conclusion
The Niva Bupa IPO has garnered significant interest among both institutional and retail investors. However, with a current nil GMP and mixed expert opinions, investors should carefully evaluate their options before applying.
Disclaimer
The views and recommendations provided in this article are based on various sources and are intended for informational purposes only. They do not constitute financial advice or recommendations for investment decisions. Investors should conduct their own research or consult with certified financial experts before making any investment choices.This overview aims to keep investors informed about the latest developments regarding the Niva Bupa IPO while highlighting key aspects that may influence their investment decisions moving forward.
